We at BIDMC, having been an active part of the development of aduhelm (aducanumab), share in the excitement of the Alzheimer’s community regarding the FDA approval for its use in early Alzheimer’s disease. It is truly historic as the first new Alzheimer’s therapy approved since 2003, and the first approved therapy to work directly on amyloid, one of the two proteins that builds up in the brain to cause Alzheimer’s disease. We are also aware of the controversy surrounding the approval of this drug, and are prepared to provide more information about this in the future.
We have been planning for this news and are building out the processes to determine who might benefit from this therapy; how to administer it safely (given the potential for significant side effects); how to provide it equitably; and how to properly monitor patients to determine their response.
Patients: If you would like to express interest in learning more about Aduhelm, please call 617-667-4074, option #5. Please leave your name, date of birth, and email address on this voicemail. You will be contacted once we are ready to screen and schedule patients for evaluation.
Healthcare providers: If you have patients who are interested in learning more about Aduhelm, please email MemoryA2Z@bidmc.harvard.edu. Please provide your name and the patient’s name, date of birth, and email address. Alternatively, you can have your patients contact us directly by phone. Patients will be contacted once we are ready to screen and schedule patients for evaluation.
We plan on updating you regularly by email and through this webpage to keep our community informed as we take these next steps in treating Alzheimer’s disease together. Please stay tuned for additional information.